Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol

Lone Baandrup, Birgitte Fagerlund, Poul Jennum, Henrik Lublin, Jane L Hansen, Per Winkel, Christian Gluud, Bob Oranje, Birte Y Glenthoj, Lone Baandrup, Birgitte Fagerlund, Poul Jennum, Henrik Lublin, Jane L Hansen, Per Winkel, Christian Gluud, Bob Oranje, Birte Y Glenthoj

Abstract

Background: Treatment of schizophrenia frequently includes prolonged benzodiazepine administration despite a lack of evidence of its use. It is often difficult to discontinue benzodiazepines because of the development of dependence. We aim to assess if melatonin can facilitate the withdrawal of prolonged benzodiazepine administration in patients with schizophrenia. Furthermore, we aim to investigate the association of benzodiazepine dose reduction with the following clinically important variables: sleep, psychophysiology, cognition, social function, and quality of life.

Methods/design: Randomized, blinded, two-armed, parallel superiority trial. We plan to include 80 consenting outpatients diagnosed with schizophrenia or schizoaffective disorder, 18-55 years of age, treated with antipsychotic drug(s) and at least one benzodiazepine derivative for the last three months before inclusion.

Exclusion criteria: currently under treatment for alcohol or drug abuse, aggressive or violent behavior, known mental retardation, pervasive developmental disorder, dementia, epilepsy, terminal illness, severe co morbidity, inability to understand Danish, allergy to melatonin, lactose, starch, gelatin, or talc, hepatic impairment, pregnancy or nursing, or lack of informed consent. After being randomized to prolonged-release melatonin (Circadin®) 2 mg daily or matching placebo, participants are required to slowly taper off their benzodiazepine dose. The primary outcome measure is benzodiazepine dose at 6 months follow-up. Secondary outcome measures include sleep, psychophysiological, and neurocognitive measures. Data are collected at baseline and at 6 months follow-up regarding medical treatment, cognition, psychophysiology, sleep, laboratory tests, adverse events, psychopathology, social function, and quality of life. Data on medical treatment, cognition, psychophysiology, adverse events, social function, and quality of life are also collected at 2 and 4 months follow-up.

Discussion: The results from this trial will examine whether melatonin has a role in withdrawing long-term benzodiazepine administration in schizophrenia patients. This group of patients is difficult to treat and therefore often subject to polypharmacy which may play a role in the reduced life expectancy of patients compared to the background population. The results will also provide new information on the association of chronic benzodiazepine treatment with sleep, psychophysiology, cognition, social function, and quality of life. Knowledge of these important clinical aspects is lacking in this group of patients.

Trial registration: ClinicalTrials NCT01431092.

Figures

Figure 1
Figure 1
Flow chart of the SMART trial design.

References

    1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76. doi: 10.1093/epirev/mxn001.
    1. WHO. ICD-10, chapter V, version 2007
    1. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321–330.
    1. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK. et al.Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST) Am J Psychiatry. 2009;166:675–682. doi: 10.1176/appi.ajp.2008.08060806.
    1. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005;8:457–472. doi: 10.1017/S146114570500516X.
    1. Volz A, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2007. p. CD006391.
    1. Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry. 2010;71:103–108. doi: 10.4088/JCP.08m04818yel.
    1. Hirshkowitz M, Sharafkhaneh A. In: The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioural Neurosciences. 5. Yudovsky S, Hales R, editor. Arlington: American Psychiatric Publishing, Inc; 2008. Neuropsychiatric Aspects of Sleep and Sleep Disorders; pp. 677–704.
    1. Hollister LE, Müller-Oerlinghausen B, Rickels K, Shader RI. Clinical Uses of Benzodiazepines. J Clin Psychopharmacol. 1993;13:72S–81S. doi: 10.1097/00004714-199312001-00005.
    1. Cohrs S. Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs. 2008;22:939–962. doi: 10.2165/00023210-200822110-00004.
    1. Monti JM, Monti D. Sleep disturbance in schizophrenia. Int Rev Psychiatry. 2005;17:247–253. doi: 10.1080/09540260500104516.
    1. Maldonado MD, Reiter RJ, Perez-San-Gregorio MA. Melatonin as a potential therapeutic agent in psychiatric illness. Hum Psychopharmacol. 2009;24:391–400. doi: 10.1002/hup.1032.
    1. Monteleone P, Maj M, Fusco M, Kemali D, Reiter RJ. Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics. Schizophr Res. 1992;7:77–84. doi: 10.1016/0920-9964(92)90077-I.
    1. Kabuto M, Namura I, Saitoh Y. Nocturnal enhancement of plasma melatonin could be suppressed by benzodiazepines in humans. Endocrinol Jpn. 1986;33:405–414. doi: 10.1507/endocrj1954.33.405.
    1. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Baker G, Klassen TP, Vohra S. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med. 2005;20:1151–1158. doi: 10.1111/j.1525-1497.2005.0243.x.
    1. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Vohra S, Klassen TP, Baker G. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ. 2006;332:385–393. doi: 10.1136/bmj.38731.532766.F6.
    1. Shamir E, Laudon M, Barak Y, Anis Y, Rotenberg V, Elizur A, Zisapel N. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatry. 2000;61:373–377. doi: 10.4088/JCP.v61n0509.
    1. Suresh Kumar PN, Andrade C, Bhakta SG, Singh NM. Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:237–241. doi: 10.4088/JCP.v68n0208.
    1. Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med. 1999;159:2456–2460. doi: 10.1001/archinte.159.20.2456.
    1. Vissers FH, Knipschild PG, Crebolder HF. Is melatonin helpful in stopping the long-term use of hypnotics? A discontinuation trial. Pharm World Sci. 2007;29:641–646. doi: 10.1007/s11096-007-9118-y.
    1. Circadin: summary of product characteristics. 2010.
    1. Srinivasan V, Pandi-Perumal SR, Trahkt I, Spence DW, Poeggeler B, Hardeland R, Cardinali DP. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci. 2009;119:821–846. doi: 10.1080/00207450802328607.
    1. Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, Zisapel N. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010;8:51. doi: 10.1186/1741-7015-8-51.
    1. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007;16:372–380. doi: 10.1111/j.1365-2869.2007.00613.x.
    1. Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, Zisapel N. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007;23:2597–2605. doi: 10.1185/030079907X233098.
    1. World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects, Current 2008 version.
    1. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. E6.
    1. Institute for Rational Pharmacotherapy (IRF)
    1. Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev. 2006;3:CD005194.
    1. Ashton CH. Benzodiazepines: How they work and how to withdraw.
    1. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005;18:249–255. doi: 10.1097/01.yco.0000165594.60434.84.
    1. Frydenlund J. Benzodiazepiner - kliniske aspekter ved brug og nedtrapning. Månedsskrift for praktisk lægegerning. 1997. pp. 1433–1443.
    1. Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23:19–34. doi: 10.2165/0023210-200923010-00002.
    1. Braff DL, Light GA. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology (Berl) 2004;174:75–85.
    1. Muller TJ, Kalus P, Strik WK. The neurophysiological meaning of auditory P300 in subtypes of schizophrenia. World J Biol Psychiatry. 2001;2:9–17. doi: 10.3109/15622970109039979.
    1. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68:283–297. doi: 10.1016/j.schres.2003.09.011.
    1. Patil SP. What every clinician should know about polysomnography. Respir Care. 2010;55:1179–1195.
    1. Martin JL, Hakim AD. Wrist actigraphy. Chest. 2011;139:1514–1527. doi: 10.1378/chest.10-1872.
    1. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193–213. doi: 10.1016/0165-1781(89)90047-4.
    1. Couvee JE, Zitman FG. The Benzodiazepine Withdrawal Symptom Questionnaire: psychometric evaluation during a discontinuation program in depressed chronic benzodiazepine users in general practice. Addiction. 2002;97:337–345. doi: 10.1046/j.1360-0443.2002.00081.x.
    1. Tyrer P, Murphy S, Riley P. The Benzodiazepine Withdrawal Symptom Questionnaire. J Affect Disord. 1990;19:53–61. doi: 10.1016/0165-0327(90)90009-W.
    1. Gotzsche PC. Blinding during data analysis and writing of manuscripts. Control Clin Trials. 1996;17:285–290. doi: 10.1016/0197-2456(95)00263-4.
    1. Winkel P, Zhang N. Statistical development of quality in medicine. John Wiley & Sons; 2007.
    1. Littell R, Milliken G, Stroup W, Wolfinger R. SAS system for mixed models. Cary, NC: SAS Institute Inc; 2002.
    1. Storebo OJ, Pedersen J, Skoog M, Thomsen PH, Winkel P, Gluud C, Simonsen E. Randomised social-skills training and parental training plus standard treatment versus standard treatment of children with attention deficit hyperactivity disorder - The SOSTRA trial protocol. Trials. 2011;12:18. doi: 10.1186/1745-6215-12-18.
    1. Crowley K. Sleep and sleep disorders in older adults. Neuropsychol Rev. 2011;21:41–53. doi: 10.1007/s11065-010-9154-6.
    1. Rajji TK, Mulsant BH. Nature and course of cognitive function in late-life schizophrenia: a systematic review. Schizophr Res. 2008;102:122–140.
    1. Saha S, Chant D, McGrath J. A Systematic Review of Mortality in Schizophrenia. Is the Differential Gap Worsening Over Time? Arch Gen Psychiatry. 2007;64:1123–1131. doi: 10.1001/archpsyc.64.10.1123.
    1. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50:79–88. doi: 10.1016/S0920-9964(00)00166-3.
    1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
    1. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101:323–329.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever